BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 34220818)

  • 1. Case Report: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder Masquerading as Multiple Sclerosis: An Under-Recognized Entity?
    Zheng Y; Cai MT; Li EC; Fang W; Shen CH; Zhang YX
    Front Immunol; 2021; 12():671425. PubMed ID: 34220818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MOG antibody-associated demyelinating disease mimicking typical multiple sclerosis: A case for expanding anti-MOG testing?
    Breza M; Koutsis G; Tzartos JS; Velonakis G; Evangelopoulos ME; Tzanetakos D; Karagiorgou K; Angelopoulou G; Kasselimis D; Potagas C; Anagnostouli M; Stefanis L; Kilidireas C
    Mult Scler Relat Disord; 2019 Aug; 33():67-69. PubMed ID: 31158804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
    Bruijstens AL; Lechner C; Flet-Berliac L; Deiva K; Neuteboom RF; Hemingway C; Wassmer E; ; Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostasy K
    Eur J Paediatr Neurol; 2020 Nov; 29():2-13. PubMed ID: 33162302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
    Takai Y; Misu T; Kaneko K; Chihara N; Narikawa K; Tsuchida S; Nishida H; Komori T; Seki M; Komatsu T; Nakamagoe K; Ikeda T; Yoshida M; Takahashi T; Ono H; Nishiyama S; Kuroda H; Nakashima I; Suzuki H; Bradl M; Lassmann H; Fujihara K; Aoki M;
    Brain; 2020 May; 143(5):1431-1446. PubMed ID: 32412053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelin-oligodendrocyte glycoprotein antibody-associated disease.
    Marignier R; Hacohen Y; Cobo-Calvo A; Pröbstel AK; Aktas O; Alexopoulos H; Amato MP; Asgari N; Banwell B; Bennett J; Brilot F; Capobianco M; Chitnis T; Ciccarelli O; Deiva K; De Sèze J; Fujihara K; Jacob A; Kim HJ; Kleiter I; Lassmann H; Leite MI; Linington C; Meinl E; Palace J; Paul F; Petzold A; Pittock S; Reindl M; Sato DK; Selmaj K; Siva A; Stankoff B; Tintore M; Traboulsee A; Waters P; Waubant E; Weinshenker B; Derfuss T; Vukusic S; Hemmer B
    Lancet Neurol; 2021 Sep; 20(9):762-772. PubMed ID: 34418402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management.
    Ambrosius W; Michalak S; Kozubski W; Kalinowska A
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E.U. paediatric MOG consortium consensus: Part 2 - Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
    Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostásy K;
    Eur J Paediatr Neurol; 2020 Nov; 29():14-21. PubMed ID: 33158737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability.
    Kwon YN; Kim B; Kim JS; Mo H; Choi K; Oh SI; Kim JE; Nam TS; Sohn EH; Heo SH; Kim SB; Park KC; Yoon SS; Oh J; Baek SH; Kim BJ; Park KS; Sung JJ; Jung JH; Kim SJ; Park SH; Waters P; Kim SM
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34711644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E.U. paediatric MOG consortium consensus: Part 3 - Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
    Armangue T; Capobianco M; de Chalus A; Laetitia G; Deiva K;
    Eur J Paediatr Neurol; 2020 Nov; 29():22-31. PubMed ID: 33191096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis.
    Nepal G; Kharel S; Coghlan MA; Rayamajhi P; Ojha R
    J Neuroimmunol; 2022 Mar; 364():577812. PubMed ID: 35063726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical spectrum of anti-MOG associated acquired demyelinating disorders: Three case-reports.
    Bellinvia A; Pastò L; Razzolini L; Fratangelo R; Prestipino E; Fonderico M; Tudisco L; Amato MP
    Mult Scler Relat Disord; 2019 Aug; 33():51-54. PubMed ID: 31152967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum level of IL-1β in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD).
    Kwon YN; Kim B; Ahn S; Seo J; Kim SB; Yoon SS; Sung JJ; Choi YS; Kim SM
    J Neuroimmunol; 2020 Nov; 348():577361. PubMed ID: 32919144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders.
    Rinaldi S; Davies A; Fehmi J; Beadnall HN; Wang J; Hardy TA; Barnett MH; Broadley SA; Waters P; Reddel SW; Irani SR; Brilot F; Dale RC; Ramanathan S;
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33272955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E.U. paediatric MOG consortium consensus: Part 4 - Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
    Bruijstens AL; Breu M; Wendel EM; Wassmer E; Lim M; Neuteboom RF; Wickström R; ; Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostasy K
    Eur J Paediatr Neurol; 2020 Nov; 29():32-40. PubMed ID: 33183945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical risk factors for recurrence of myelin oligodendrocyte glycoprotein antibody-associated disease.
    Wang J; Yang K; Zhang F; Yi Y; Wang J
    Mult Scler Relat Disord; 2023 Sep; 77():104879. PubMed ID: 37442076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MOG-related disorders: A new cause of imaging-negative myelitis?
    Macaron G; Ontaneda D
    Mult Scler; 2020 Apr; 26(4):511-515. PubMed ID: 30931813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelitis with normal spinal cord MRI: don't forget anti-MOG antibodies disease!
    Grangeon L; Hébant B; Guillaume M; Ahtoy P; Lefaucheur R
    Acta Neurol Belg; 2020 Aug; 120(4):945-946. PubMed ID: 32157671
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical and Imaging Features of Patients With Encephalitic Symptoms and Myelin Oligodendrocyte Glycoprotein Antibodies.
    Wang J; Qiu Z; Li D; Yang X; Ding Y; Gao L; Liu A; Song Y; Li C; Gao R; Wang L; Wu L; Jia L; Guo D; Zhou A; Jia J; Huang L; Qu M; Gao L; Dong H; Hao J; Liu Z
    Front Immunol; 2021; 12():722404. PubMed ID: 34691028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory T Cells Increase After rh-MOG Stimulation in Non-Relapsing but Decrease in Relapsing MOG Antibody-Associated Disease at Onset in Children.
    Horellou P; de Chalus A; Giorgi L; Leroy C; Chrétien P; Hacein-Bey-Abina S; Bourgeois C; Mariette X; Serguera C; Le Grand R; Deiva K
    Front Immunol; 2021; 12():679770. PubMed ID: 34220827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Sclerosis Is Rare in Epstein-Barr Virus-Seronegative Children with Central Nervous System Inflammatory Demyelination.
    Nourbakhsh B; Cordano C; Asteggiano C; Ruprecht K; Otto C; Rutatangwa A; Lui A; Hart J; Flanagan EP; James JA; Waubant E
    Ann Neurol; 2021 Jun; 89(6):1234-1239. PubMed ID: 33704815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.